Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled...
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR) PR Newswire DUBLIN, Sept. 3, 2024 – THERAKOS, the world's only fully...
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire DUBLIN, Aug. 6, 2024 Achieves Second Quarter Net Sales of $514.3 Million, Reflecting...
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S. PR Newswire DUBLIN, Aug. 6, 2024 – Acthar Gel is the...
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire DUBLIN and LUXEMBOURG, Aug. 5, 2024 Divestiture Advances Mallinckrodt's Strategic Priorities to...
Mallinckrodt to Report Earnings Results for Second Quarter 2024 PR Newswire DUBLIN, Aug. 1, 2024 DUBLIN, Aug. 1, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global...
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress PR...
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week® (DDW) PR Newswire DUBLIN, May 18, 2024 – Two...
Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance PR Newswire DUBLIN, May 9, 2024 Achieves First Quarter Net Sales of $467.8 Million, Reflecting 10.2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.